CRISPR Therapeutics AG (LTS:0VRQ) Moat Score: 7/10 (As of Jul. 04, 2026)


LTS:0VRQ CRISPR Therapeutics AG LTS:0VRQ
46 GF Score
Price $59.25
GF Value $2.74
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Moat Score?

CRISPR Therapeutics AG LTS:0VRQ 46 Moat Score is 7 as of Jul. 04, 2026. GuruFocus rates LTS:0VRQ with a GF Score™ of 46/100 and a GF Value™ of $2.74 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,399 Biotechnology companies, CRISPR Therapeutics AG ranks better than 99.57% on this metric.

CRISPR Therapeutics AG has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

CRISPR Therapeutics AG has Wide Moat: CRISPR Therapeutics possesses a wide moat due to its valuable intellectual property in gene editing and strong R&D capabilities. Its significant regulatory barriers and innovation provide durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes CRISPR Therapeutics AG might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

CRISPR Therapeutics AG  (LTS:0VRQ) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

CRISPR Therapeutics AG Moat Score Related Terms

LTS:0VRQ vs ORKA, TVTX, MANE: Moat Score Comparison

For the Biotechnology subindustry, CRISPR Therapeutics AG's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CRISPR Therapeutics AG Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Moat Score distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Moat Score falls into.


LTS:0VRQ
46GF Score
CRISPR Therapeutics AG LTS:0VRQ
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
CRISPR Therapeutics AG (LTS:0VRQ) has a Moat Score of 7 as of Jul. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, CRISPR Therapeutics AG ranks #6 out of 1399 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is CRISPR Therapeutics AG's Moat Score too high?
CRISPR Therapeutics AG's current Moat Score is 7. The Biotechnology industry median Moat Score is 2.00. CRISPR Therapeutics AG's value of 7 is 250% above this industry median. Based on the distribution chart, CRISPR Therapeutics AG ranks #6 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CRISPR Therapeutics AG has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Moat Score compare to ORKA and TVTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #6 out of 1399 companies for Moat Score. This places CRISPR Therapeutics AG in the top 0% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. CRISPR Therapeutics AG's value of 7 is 250% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CRISPR Therapeutics AG's current Moat Score of 7 is 250% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CRISPR Therapeutics AG's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.74, compared to a current price of $59.25 — trading 2062.4% above its estimated fair value. The current Moat Score is 7 and 250% above the Biotechnology industry median of 2.00. CRISPR Therapeutics AG's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Moat Score is 7 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of $59.25 is trading 2062.4% above its estimated GF Value™ of $2.74. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for LTS:0VRQ:

  • Moat Score: 7
  • GF Value™: $2.74 vs. price of $59.25 (2062.4% above fair value)
  • GF Score™: 46/100 with 3 warning signs
  • Industry Position: 250% above the Biotechnology median (#6 of 1399)

No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
46GF Score

Get the complete analysis for LTS:0VRQ

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.25
Price
$2.74
GF Value